Abstract:Background: Early and accurate diagnosis is crucial to managing biliary tract carcinoma (BTC). But18F-fluorodeoxyglucose (18F-FDG) PET/CT has deficiencies. Novel radiolabeled fibroblast activation protein (FAP) inhibitors, which present a promising alternative to 18F-FDG, allowed for the selective targeting of tumors.Methods: A prospective study (NCT 05264688) was performed between January 2022 through July 2022. Fifty participants were scanned using 68Ga-FAPI and 18F-FDG PET/CT and acquired pathological tissue.We employed the Wilcoxon signed-rank test to compare the uptake of 68Ga-FAPI and 18F-FDG, and the McNemar test was used to compare the diagnostic efficacy between the two tracers. Spearman or Pearson correlation was used to assess the association between 68Ga-FAPI PET/CT and clinical indexes.Findings: In total, 47 participants (mean age 59.09±10.98 [range 33–80 years]) were evaluated. The 68Ga-FAPI detection rate was greater than 18F-FDG in primary tumors (97.62% vs. 85.71%), nodal metastases (90.05% vs. 87.06%), distant metastases (100% vs. 83.67%). The uptake of 68Ga-FAPI was higher than 18F-FDG in primary lesions (intrahepatic cholangiocarcinoma: 18.95±7.47 vs. 11.86±0.70, p=0.001; extrahepatic cholangiocarcinoma:14.57±6.16 vs. 8.80±4.74, p=0.004), abdomen and pelvic cavity nodal metastases (6.91±6.56 vs. 3.94±2.83, p<0.001), distant metastases (pleural, peritoneum, omentum, and mesentery: 6.37±4.21 vs. 4.50±1.96, p=0.01; Bone: 12.15±6.43 vs. 7.51±4.54, p=0.008). There was a significant correlation between 68Ga-FAPI uptake and FAP expression (Spearman r=0.432, p=0.009), carcinoembryonic antigen (CEA) (Pearson r=0.364, p=0.012), and platelet (PLT) (Pearson r=0.35, p=0.016). Meanwhile, a significant relationship between 68Ga-FAPI metabolic tumor volume (MTV) and carbohydrate antigen199 (CA199) (Pearson r=0.436, p=0.002) was confirmed.Interpretation: 68Ga-FAPI preceded 18F-FDG in diagnosing BTC to a certain extent. The correlation between 68Ga-FAPI PET/CT indexes and FAP expression, CEA, PLT, and CA199 were confirmed.Trial Registration: This clinical trial was registered on clinicaltrails.gov (NCT 05264688)Funding: Key Research and Development Program of Hubei Province (2021BCA114), Research Fund of the Health Commission of Hubei Province (WJ2021M255), Cancer research and translational platform project of Zhongnan Hospital of Wuhan University (ZLYNXM202004).Declaration of Interest: All authors have no conflicts of interest or financial ties to discloseEthical Approval: This study was approved by the Clinical Research Ethics Committee of Zhongnan Hospital of Wuhan University. Before participating in this study, the participants must provide written informed consent.

[68Ga]Ga-FAP-2286—Synthesis, Quality Control and Comparison with [18F]FDG PET/CT in a Patient with Suspected Cholangiocellular Carcinoma

Noninvasive imaging of FAP expression using positron emission tomography: A comparative evaluation of a [18F]-labeled glycopeptide-containing FAPI with [18F]FAPI-42

Preclinical Evaluation and a Pilot Clinical Positron Emission Tomography Imaging Study of [68Ga]ga-Fapi-fuscc-ii.

PET Imaging of Fibroblast Activation Protein in Various Types of Cancer Using 68Ga-FAP-2286: Comparison with 18F-FDG and 68Ga-FAPI-46 in a Single-Center, Prospective Study

68Ga-FAP-2286 PET of Solid Tumors: Biodistribution, Dosimetry, and Comparison with 18F-FDG

Translational imaging of the fibroblast activation protein (FAP) using the new ligand [68Ga]Ga-OncoFAP-DOTAGA

An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use

Rational Design, Pharmacomodulation, and Synthesis of [ 68 Ga]Ga-Alb-FAPtp-01, a Selective Tumor-Associated Fibroblast Activation Protein Tracer for PET Imaging of Glioma

18F-labeled tracers targeting fibroblast activation protein

Radiosynthesis, preclinical evaluation and pilot clinical PET imaging study of a 18F-labeled tracer targeting fibroblast activation protein

[68Ga]Ga-labeled FAPI Conjugated with Gly-Pro Sequence for PET Imaging of Malignant Tumors

Diagnostic efficacy of [68Ga]Ga-DOTA-GPFAPI-04 in patients with solid tumors in a head-to-head comparison with [18F]F-FDG: results from a prospective clinical study

Head-to-head Intra-individual Comparison of [68Ga]-FAPI and [18F]-FDG PET/CT in Patients with Bladder Cancer

68Ga-Labeled Fibroblast Activation Protein Inhibitor PET/ CT in the Clinical Diagnosis and Management of Breast Cancer: Comparison with [18F]FDG PET/CT

[68Ga]Ga-DOTAGA-Glu(FAPi)2 Shows Enhanced Tumor Uptake and Theranostic Potential in Preclinical PET Imaging

A Head-to-Head Comparison of 68Ga-LNC1007 and 2-18F-FDG/68Ga-FAPI-02 PET/CT in Patients With Various Cancers

Clinical Prospective Study of Gallium 68 ( <sup>68</sup>ga)–labeled Fibroblast-Activation Protein Inhibitor PET/CT in the Diagnosis of Biliary Tract Carcinoma

FAPI PET: Fibroblast Activation Protein Inhibitor Use in Oncologic and Nononcologic Disease

A comparison of [18F]AlF- and 68Ga-labeled dual targeting heterodimer FAPI-RGD in malignant tumor: preclinical evaluation and pilot clinical PET/CT imaging

68Ga/177Lu-Labeled Theranostic Pair for Targeting Fibroblast Activation Protein with Improved Tumor Uptake and Retention

Preclinical evaluation and first-in-human study of [18F]AlF-FAP-NUR for PET imaging cancer-associated fibroblasts